(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
This Week In Space podcast: Episode 204 — A New NASA - 2Figure out how to Detect the Best Rooftop Substitution Choices
- 3Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- 4Undeniably popular Historical centers: Where Craftsmanship and History Meet
- 5James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
- Tesla Stock Hasn’t Looked This Cheap in a While
- The Response to Self-improvement: Embracing a Development Outlook
- Which Switch Game Do You Suggest? Share Your Decision
- Israeli military says it hit dozens of military facilities in Tehran
- 5 Pizza Fixings That Characterize Your Character
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- FDA proposes use of sunscreen ingredient popular in other countries
- Vote In favor of Your Favored Kind Of Attire
- Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
